IN-VIVO SELECTION DURING PEFLOXACIN THERAPY OF A MUTANT OF STAPHYLOCOCCUS-AUREUS WITH 2 MECHANISMS OF FLUOROQUINOLONE RESISTANCE

Citation
J. Tankovic et al., IN-VIVO SELECTION DURING PEFLOXACIN THERAPY OF A MUTANT OF STAPHYLOCOCCUS-AUREUS WITH 2 MECHANISMS OF FLUOROQUINOLONE RESISTANCE, Antimicrobial agents and chemotherapy, 38(5), 1994, pp. 1149-1151
Citations number
24
Categorie Soggetti
Pharmacology & Pharmacy",Microbiology
ISSN journal
00664804
Volume
38
Issue
5
Year of publication
1994
Pages
1149 - 1151
Database
ISI
SICI code
0066-4804(1994)38:5<1149:ISDPTO>2.0.ZU;2-5
Abstract
Staplylococcus aureus BM4626 (ciprofloxacin MIC, 0.5 mu g/ml) and BM46 27 (ciprofloxacin MIC, 32 mu g/ml) were isolated from the same patient before and during pefloxcin therapy for septic tibial nonunion, respe ctively. The two strains had similar serotypes and indistinguishable p hage types and SmaI-generated restriction fragment length polymorphism s. Portions of the gyrA (codons 60 to 120) and the gyrB (codons 420 to 480) genes of each clinical isolate were amplified by PCR and sequenc ed. Strain BM4627 had a serine-to-leucine substitution resulting from a cytosine-to-thymidine mutation at codon 84 of gvrA relative to the s equence of the gvrA gene of BM4626. Norfloxacin accumulation, measured in a whole-cell uptake assay, was significantly lower in BM4627 than BM4626. These data indicate that double mutants can be selected in viv o under fluoroquinolone therapy.